The strongest cannabinoid depends on whether you’re counting natural or synthetic compounds. Among those found in the cannabis plant, THCP (tetrahydrocannabiphorol) holds the title, binding to the brain’s primary cannabinoid receptor with roughly 33 times the affinity of regular THC. Among lab-created compounds, a synthetic called HU-210 is even more potent, with a binding affinity up to 60 times stronger than THC at the same receptor.
But “strongest” isn’t as straightforward as a single number. How tightly a molecule grips a receptor is one thing. Whether it fully activates that receptor, how the body processes it, and what the actual experience feels like are all separate questions.
THCP: The Strongest Natural Cannabinoid
THCP was first identified in 2019 by Italian researchers analyzing a medicinal cannabis variety called FM2. It had never been documented before because it exists in extremely small quantities in the plant and required advanced mass spectrometry to detect. The compound has the same core structure as THC, with one critical difference: its side chain contains seven carbon atoms instead of five.
That two-carbon difference matters enormously. The length of a cannabinoid’s side chain directly determines how well it fits into the CB1 receptor, the receptor responsible for the psychoactive effects of cannabis. Researchers found that THCP binds to the human CB1 receptor with a Ki value of 1.2 nanomolar, compared to 40 nanomolar for regular THC. In pharmacology, a lower Ki means a tighter fit, so THCP latches on about 33 times more effectively. In animal studies, THCP also behaved as a full agonist at the same dose where THC acts as only a partial agonist, meaning it activated the receptor more completely.
For context, THCP’s binding affinity is nearly identical to CP-55,940, a well-known synthetic cannabinoid used in lab research (Ki of 0.9 nanomolar). The fact that a plant-derived compound rivals a purpose-built synthetic one is part of what made the discovery remarkable. Alongside THCP, the same team also identified CBDP, a seven-carbon version of CBD, though its effects have received far less attention.
How the Carbon Chain Changes Potency
Cannabis produces a family of THC-like molecules that differ mainly in the length of their side chain. A cannabinoid needs at least three carbons in that chain to produce any psychoactive effects at all. From there, potency scales upward with each additional carbon. Regular THC has five. THCB (tetrahydrocannabutol), with four carbons, shows about three times THC’s binding affinity, with a Ki of 15 nanomolar. THCP, with seven carbons, jumps to 33 times.
Another variant, THCH (tetrahydrocannabihexol), has six carbons and likely falls somewhere between THCB and THCP in potency, but it occurs in such tiny amounts in the plant that researchers haven’t been able to fully test it. None of these minor cannabinoids are present in cannabis in significant concentrations, which is why standard marijuana products are still dominated by regular five-carbon THC.
Synthetic Cannabinoids Are Stronger Still
Lab-created cannabinoids surpass anything the cannabis plant produces. HU-210, developed for research purposes, has a CB1 binding affinity as low as 0.06 nanomolar, making it roughly 60 to 600 times more potent than THC depending on the specific assay used. Other well-studied synthetics include CP-55,940 (Ki of 0.5 to 5 nanomolar) and WIN-55,212-2 (Ki of about 1.9 nanomolar). All of these function as full agonists, meaning they push the CB1 receptor to maximum activation.
This full-agonist property is what makes synthetic cannabinoids categorically more dangerous than plant-derived THC. Regular THC is a partial agonist. Think of it like a dimmer switch: THC turns the receptor partway on, and no matter how much you consume, there’s a ceiling to how strongly it can activate that receptor. Full agonists have no such ceiling. They can drive the receptor to 100% activation, which is why synthetic cannabinoids found in street products (often sold under names like “Spice” or “K2”) are associated with seizures, organ damage, and deaths in ways that plant cannabis is not.
Full Agonists vs. Partial Agonists
The distinction between full and partial agonism is arguably more important than raw binding affinity when it comes to real-world effects. In animal studies, THC can mimic many of the behavioral effects of full agonists at low doses, which is why it still gets you high despite being pharmacologically “weak.” But as the dose of a full agonist increases, the gap between it and THC widens dramatically. Researchers training rats to distinguish between a full agonist and THC found that progressively higher training doses required disproportionately more THC to produce the same effect, while other full agonists scaled more linearly.
This means that THCP’s combination of high binding affinity and full-agonist behavior could make it meaningfully more intense than THC in ways that go beyond what the 33x binding number alone suggests. At the same milligram dose used in animal testing, THCP produced stronger pain-blocking, temperature-lowering, and movement-reducing effects than THC.
Your Body’s Own Cannabinoids Are Weaker
Your brain naturally produces two main cannabinoids: anandamide and 2-AG. Both are far less potent than THC, and they work differently from each other. Anandamide binds to CB1 receptors with higher affinity than 2-AG, but it’s only a partial agonist and gets broken down almost immediately. 2-AG is a full agonist but binds more loosely, and it’s also metabolized quickly.
Despite its lower receptor affinity, 2-AG is now considered the more important signaling molecule of the two. It’s present in the brain at concentrations 200 to 1,000 times higher than anandamide, and it appears to be the primary molecule responsible for the brain’s retrograde signaling system, the process by which receiving neurons send feedback signals to sending neurons. The reason external cannabinoids like THC produce such pronounced effects is partly that they bind more tightly than these natural compounds and partly that they linger far longer before the body can break them down.
Health Risks Scale With Potency
Higher-potency cannabinoids carry measurably higher risks, particularly for psychosis. A large study of first-episode psychosis patients found that higher-potency cannabis use was associated with a 60% increased risk of psychotic disorder compared to non-use, while lower-potency use showed no significant increase. Daily use of high-potency cannabis was linked to a more than threefold increase in psychosis relapse within two years.
These findings come from research on conventional high-THC cannabis, not THCP or synthetics. The risks from compounds many times stronger than standard THC are largely unstudied in humans, which is part of what makes the growing availability of novel cannabinoids concerning. THCP-containing products are now sold in some markets as hemp derivatives, exploiting regulatory gaps around minor cannabinoids. The FDA has issued ongoing warning letters to companies selling cannabis-derived products, though enforcement has focused primarily on CBD and delta-8 THC rather than newer compounds like THCP specifically.
If you encounter products marketed as containing THCP, THCH, or similar novel cannabinoids, the practical reality is that there is essentially no human dosing data, no standardized manufacturing, and no regulatory oversight ensuring what’s on the label matches what’s in the product. The potency of these compounds means that even small errors in concentration could produce dramatically different effects than intended.